Background-Myocardial reperfusion after ischemia (I/R), although an effective approach in rescuing the ischemic myocardium, can itself trigger several adverse effects including aberrant remodeling of the myocardium and its extracellular matrix. Tissue inhibitor of metalloproteinases (TIMPs) protect the extracellular matrix against excess degradation by matrix metalloproteinases (MMPs). TIMP4 levels are reduced in myocardial infarction; however, its causal role in progression of post-I/R injury has not been explored. Methods and Results-In vivo I/R (20-minute ischemia, 1-week reperfusion) resulted in more severe systolic and diastolic dysfunction in TIMP4 −/− mice with enhanced inflammation, oxidative stress (1 day post-I/R), hypertrophy, and interstitial fibrosis (1 week). After an initial increase in TIMP4 (1 day post-I/R), TIMP4 mRNA and protein decreased in the ischemic myocardium from wild-type mice by 1 week post-I/R and in tissue samples from patients with myocardial infarction, which correlated with enhanced activity of membrane-bound MMP, membrane-type 1 MMP. By 4 weeks post-I/R, wild-type mice showed no cardiac dysfunction, elevated TIMP4 levels (to baseline), and normalized membranetype 1 MMP activity. TIMP4-deficient mice, however, showed exacerbated diastolic dysfunction, sustained elevation of membrane-type 1 MMP activity, and worsened myocardial hypertrophy and fibrosis. Ex vivo I/R (20-or 30-minute ischemia, 45-minute reperfusion) resulted in comparable cardiac dysfunction in wild-type and TIMP4 −/− mice. Conclusions-TIMP4 is essential for recovery from myocardial I/R in vivo, primarily because of its membrane-type 1 MMP inhibitory function. TIMP4 deficiency does not increase susceptibility to ex vivo I/R injury. Replenishment of myocardial TIMP4 could serve as an effective therapy in post-I/R recovery for patients with reduced TIMP4. post-I/R corresponded to diastolic dysfunction, which was reversed by 4 weeks post-I/R because TIMP4 levels were normalized. TIMP4 deficiency, however, led to systolic and diastolic dysfunction at 1 week, which progressed to severe diastolic dysfunction by 1 month post-I/R. These data strongly suggest that TIMP4 insufficiency is a major determinant of the adverse structural and functional outcomes post-I/R.
P ostischemic myocardial reperfusion (I/R) is an effective therapeutic approach in salvaging the ischemic myocardium; however, it can also trigger several unfavorable events. 1 Adverse remodeling of the myocardial extracellular matrix (ECM) is one of the key aspects of the postischemiareperfusion (I/R) injury. ECM turnover and remodeling is mediated through the function of ECM-degrading enzymes, matrix metalloproteinases (MMPs), and their physiological inhibitors, tissue inhibitor of metalloproteinases (TIMPs). [2] [3] [4] ECM is the structural scaffold for the myocardial tissue and also provides a microenvironment for several growth factors and cytokines. As such, abnormal ECM turnover in heart disease can result in activation of several cellular and molecular events in addition to structural instability. Among the 4
TIMPs, TIMP4 exhibits a tissue-specific expression pattern primarily in the heart and brain, 5 and TIMP4 has been identified as the only TIMP that could serve as a biomarker in patients with different cardiomyopathies. [6] [7] [8] [9] TIMP4-deficient mice exhibited increased rate of left ventricular (LV) rupture after myocardial infarction (MI) 10 ; however, the direct role of TIMP4 in ischemia-reperfusion injury has not yet been examined.
Clinical Perspective on p 662
In this study, we investigated whether TIMP4 is a critical factor in progression of myocardial injury after ischemia-reperfusion using an in vivo and an ex vivo model. In wild-type mice, a decrease in TIMP4 levels at 1 week post-I/R corresponded to diastolic dysfunction, which was reversed by 4 weeks post-I/R because TIMP4 levels were normalized. TIMP4 deficiency, however, led to systolic and diastolic dysfunction at 1 week, which progressed to severe diastolic dysfunction by 1 month post-I/R. These data strongly suggest that TIMP4 insufficiency is a major determinant of the adverse structural and functional outcomes post-I/R.
Methods
Detailed Methods is described in the Data Supplement.
Experimental Animals
Wild-type C57BL/6 (Jackson Laboratories) and TIMP4 −/− mice (Texas A&M Institute for Genomic Medicine) in C57BL/6 background were used as before. 11 All animal experiments were performed in accordance with Canadian Council on Animal Care Guidelines and regulations of Animal Care and Use Committee at University of Alberta.
Myocardial Ischemia-Reperfusion In Vivo
In vivo ischemia-reperfusion (I/R) was induced in 10-to 11-weekold male mice of either genotype by temporary ligation of the left anterior descending artery as before. 12 After 20 minutes of ischemia, 
Human Explanted Heart Tissue
Cardiac tissues from patients with post-MI heart failure were collected from the explanted hearts at the time of cardiac transplantation as part of the Human Explanted Heart Program (HELP) at the Mazankowski Alberta Heart Institute (Edmonton, Alberta, Canada). Noninfarct ischemic myocardial tissue was used in this study. Nonfailing control hearts were obtained through the Human Organ Procurement and Exchange (HOPE) program (Edmonton, Alberta, Canada). All experiments were performed in accordance with the institutional guidelines and were approved by Institutional Ethics Committee. Informed consent was obtained from all subjects.
Cardiac Function Analysis by Echocardiography
Systolic and diastolic cardiac functions were determined by noninvasive transthoracic echocardiography in anesthetized mice (0.75% isoflurane) as before. 12, [14] [15] [16] Modified parasternal long axis EKV loops were also used to measure ejection fraction by Simpson's method. M-mode images were used to measure LV chamber sizes and wall thicknesses. The wall motion score index was calculated on the basis of the American Society of Echocardiography-recommended assessment of wall motion function. 17, 18 An increase in wall motion score index (>1) indicates suppressed LV systolic wall motion.
Isolation and Culture of Adult Cardiac Fibroblasts and Myocytes
Cardiac fibroblasts (cFB) and myocytes (cMYO) were isolated from adult wild-type (WT) and TIMP4 −/− mice as previously described. 19 Cells were subjected to hypoxia, ischemia, ischemia-reperfusion, or cytokines as described in Methods in the Data Supplement.
Isolated Heart Ischemia-Reperfusion (Ex Vivo)
Male mice of either genotype, 10 to 11 weeks of age, were heparinized and anesthetized, and hearts were excised and perfused on a Langendorff apparatus at a constant pressure of 80 mm Hg with oxygenated modified Krebs-Henseleit solution. 12 EDTA was not included in the perfusion solution because its MMP-inhibitory properties would interfere with the objective of our study to decipher the role of TIMP4 in I/R. LV pressure was monitored using the PowerLab system (ADInstruments, Australia). After 15 minutes of baseline recording, hearts were subjected to 20 minutes (or 30 minutes) of global ischemia followed by 45 minutes of reperfusion. The coronary effluent (before ischemia and after reperfusion) was collected and used to determine creatine kinase levels, as a measure of myocyte death, using a commercial kit (BioAssay).
Protein Analysis, Western Blotting, Gelatin Zymography, Gelatinase, and membrane-Type 1 MMP Activity Assays Protein extraction, Western immunoblotting, gelatin zymography, and total gelatinase activity (EnzCheck fluorescent-based activity assays, Molecular Probes) were measured as before. 14, 15 Western blots for membrane-type 1 MMP (MT1-MMP) was performed on membrane protein fraction, 15 and its activity was measured using a specific MT1-MMP fluorogenic substrate (Calbiochem) as described. 16, 20 Inhibitory Activity of TIMPs Against MT1-MMP, MMP2, and MMP9
Recombinant MT1-MMP (catalytic domain, Calbiochem), pro-MMP2, pro-MMP9, and TIMPs (rTIMP1, -2, -3, -4) were purchased from R&D systems. Fluorescence-tagged substrates specific to MT1-MMP or MMP2/9 were purchased from Calbiochem. For all 3 assays, the same concentrations of the fluorescence-tagged substrate (30 μmol/L) and the recombinant MMP enzymes (100 ng/mL) were used. Recombinant pro-MMP2 and pro-MMP9 were activated by preincubation with APMA. 21, 22 TCNB assay buffer (Tris, CaCl 2 , NaCl, Brij-35) was used for MMP2 and MMP9 activity assays, and modified TCNB buffer for MT1-MMP activity assay as before. 16 In parallel experiments, increasing amounts of recombinant TIMPs (rT-IMP, 0, 0.1, 1, 5, 10, 20, 40, 80 ng) were used to compare the inhibitory function of each TIMP against rMMP2, rMMP9, or rMT1-MMP. Activities of MT1-MMP (Ex=328 nm, Em=400 nm), MMP2, and MMP9 (Ex=280 nm, Em=360 nm) were measured using Spectra max M5 microplate reader (Molecular devices).
RNA Expression Analysis
Total RNA was extracted using TriZol Reagent (Invitrogen) and mRNA expression analysis was performed by TaqMan RT-PCR as before. 15, 23 Hypoxanthine-guanine phosphoribosyltransferase-1 was used as the internal control for mouse samples and 18S for human samples. Taqman primers and probes were used to measure the expression of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP1), TIMP1, TIMPs, MMPs, MT1-MMP, procol I-α1, and procol III-α1 as before.
15,24

Dihydroethidium, Neutrophil, and Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling Staining
Dihydroethidium staining was performed on cryosections as before, 25 visualized using a fluorescence microscope (Olympus IX81), quantified using Metamorph Basic software (version 7.7.0.0), and reported as dihydroethidium fluorescence intensity/field. Neutrophil staining was performed as before, 24 using anti-mouse neutrophil antibody with Cy3-labeled anti-rat secondary antibody, and nuclear DAPI (4',6-diamidino-2-phenylindole) staining. Neutrophil density was determined using Metamorph Basic software (version 7.7.0.0) and reported as neutrophil counts per field.
Myocardial injury was determined by assessing apoptosis by in situ detection of DNA fragmentation using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay kit (Invitrogen) according to manufacturer's instructions as before. 12 Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells (yellow, resulting from green and red overlap) were counted per field using the MetaMorph software (Basic version 7.7.0.0) and expressed as percentage of total number of cells per field.
Histological Analyses
Freshly excised hearts were arrested in diastole in 1 mol/L KCl, fixed in 10% buffered formalin, paraffin-embedded, and processed for trichrome, picrosirius red, and wheat germ agglutinin staining as before. 12 Myocyte cross-sectional area and collagen content for wheat germ agglutinin and picrosirius red staining were quantified using Metamorph Basic software (version 7.7.0.0).
Statistical Analyses
Reported averaged values are mean±SEM. Statistical analysis was performed using the IBM SPSS Statistics 19 software. One-way ANOVA was followed by Tukeys multiple comparison test if the results attained statistical significance (P<0.05). Pairwise comparisons were made between the WT and TIMP4 −/− sham, 1-week I/R and 4-week I/R groups using the Student t test. For ex vivo studies, 2-way repeated-measures ANOVA was used to compare WT and TIMP4 −/− groups. Where needed, we first confirmed normal distribution (Shapiro-Wilk Statistic; P<0.05) and homogenous variance (Levene test), then performed statistical analyses as described above. Statistical significance was recognized when P<0.05 (2 sided).
Results
TIMP4 is Critical in Myocardial Recovery From Ischemia-Reperfusion Injury In Vivo
In WT mice, TIMP4 protein and mRNA levels decreased in the ischemic myocardium at 1 week post-I/R (Figure 1Ai and  1Aii) . Interestingly, myocardial tissue from patients with post-MI heart failure showed a similar decrease in TIMP4 protein and mRNA levels (Figure 1Bi and 1Bii) . To determine if this reduction in TIMP4 promotes the post-I/R pathology or if it is simply a bystander, we subjected TIMP4-deficient mice to in vivo myocardial I/R. At 1 week post I/R, TIMP4 −/− mice, but not WT mice, exhibited systolic dysfunction, determined by reduced ejection fraction (Figure 1Di ) and elevated wall motion score index (Figure 1Dii ). Diastolic dysfunction was more severe in TIMP4 −/− mice, determined by a significantly 
Enhanced Myocardial Fibrosis and Hypertrophy in TIMP4
−/− Mice Post-I/R Next, we assessed the impact of TIMP4 deficiency on myocardial hypertrophy and fibrosis, which are often associated with diastolic and systolic dysfunction. Picrosirius red staining and fluorescence microscopy showed enhanced collagen content in the ischemic region of TIMP4 −/− compared with WT hearts at 1 week post-I/R (Figure 2Ai and 2Aii) . In addition, mRNA expression of collagen type-I was increased to a greater extent in TIMP4 −/− -I/R hearts (Figure 2Bi ), whereas the elevation in collagen type-III mRNA was similar between genotypes (Figure 2Bii) . In addition, TIMP1 levels were significantly increased in TIMP4 −/− -I/R hearts (Figure 2Biii ), which has been strongly linked to myocardial fibrosis in patients and in animal models. 23, 26 Assessment of myocardial hypertrophy by cardiomyocyte cross-sectional area in wheat germ agglutinin-stained sections (Figure 2Ci and 2Cii) and heart weight-to-tibial length ratio ( Figure 2D ) indicate greater myocardial hypertrophy in TIMP4 −/− compared with WT mice at 1 week post-I/R, primarily in the ischemic myocardium (Figure 2Ci and 2Cii) . Therefore, the more severe diastolic dysfunction in TIMP4 −/− -I/R mice is associated with enhanced fibrosis and hypertrophy.
Excess Oxidative Stress and Inflammation in TIMP4
−/− Hearts at 1 Day Post-I/R
In identifying the early molecular and cellular events that lead to the observed diastolic dysfunction in TIMP4 −/− -I/R hearts, we found that at 1 day post-I/R, superoxide levels were markedly elevated in the ischemic region of TIMP4 −/− -I/R hearts, determined by increased number of cells positively stained for dihydroethidium (Figure 3Ai and 3Aii) . Further, elevated neutrophil infiltration (Figure 3Bi and 3Bii) and enhanced expression of inflammatory markers, IL-6 and MCP1 (Figure 3Ci and 3Cii) were detected in the ischemic myocardium of TIMP4 −/− compared with WT mice. Concomitantly, enhanced myocardial injury, determined by a larger number of apoptotic cells, was observed in TIMP4 −/− ischemic myocardium (Figure 3Di  and 3Dii) . The oxidative stress and inflammation subsided by 1 week post-I/R (data not shown), which is consistent with the transient nature of these events after injury.
We investigated how these early events impact TIMP4 levels in myocardial cells using cultured adult cardiomyocyte (cMYO) and cardiac fibroblast (cFB) under different conditions, hypoxia, ischemia, I/R, and cytokine that were elevated in vivo (IL-6, MCP1, MCP1+IL-6; Figures I and IIA in the Data Supplement). After hypoxia and I/R, TIMP4 mRNA increased in the cMYO (but not cFB), whereas exposure to IL-6 or IL-6+MCP1 increased TIMP4 mRNA in cFB. Although ischemia triggered an increase in TIMP2 and TIMP3 levels in cMYO, it did not alter TIMP4 levels. Next, we asked how these findings correlate with early in vivo changes in 
Absence of TIMP4 Inhibitory Function Elevates MT1-MMP Activity
Because tissue proteolysis is one of the major contributors to overall cardiac remodeling, fibrosis, and diastolic dysfunction, we measured the levels and the activity of several key MMPs and their inhibitors, TIMPs that could contribute to these events. At 1 week post-I/R, in vitro gelatin zymography showed elevated MMP2 (pro-and cleaved) levels in the ischemic myocardium of TIMP4 −/− -I/R mice (Figure 4Ai-4Aiii) , whereas the increase in MMP9 levels did not reach statistical significance (Figure 4Ai and 4Aiv) . This was accompanied by increased mRNA expression for MMP2 but not MMP9, whereas MMP7, -8, -9, or -13 were not elevated in either group post-I/R ( Figure IIIAi Figure 4C ). This was consistent with the elevated MT1-MMP activity in the ischemic myocardium from patients ( Figure 4D) .
Next, we compared the inhibitory function of TIMP4, compared with other TIMPs, against MT1-MMP, MMP2, and MMP9, the MMPs that were elevated in TIMP4 −/− -I/R hearts. In vitro assessment of the inhibitory function of the 4 TIMPs against MT1-MMP, MMP2, and MMP9 showed that TIMP4 is as potent as TIMP3 and second to the inhibitory effects of TIMP2 against MT1-MMP, whereas TIMP1 lacks inhibitory functions against rMT1-MMP (Figure 4Di ). All TIMPs inhibited rMMP2 and rMMP9 with similar potency. The rTIMPs used here are not glycosylated; glycosylation could impact their MMP-inhibitory function, whereas full-length MT1-MMP could interact differently with TIMPs compared with its catalytic domain used in this experiment. Based on our findings, it is plausible that the elevated TIMP1 levels in TIMP4 −/− -I/R hearts suppressed the activity of MMP2 and MMP9 (leading to unaltered total gelatinase activity), whereas MT1-MMP activity remained elevated.
TIMP4 Is Essential for Chronic Recovery From I/R Injury
To investigate how TIMP4 deficiency influences the long-term myocardial recovery from I/R injury, we followed up cardiac remodeling and function in WT heart weight-to-tibial length ratio ( Figure 5B ) in this group. Interestingly, by 4 weeks post-I/R, although the increase in myocyte cross-sectional area (Figure 5Ci and 5Cii) and myocardial fibrosis ( Figure 5D ) became more pronounced in TIMP4 −/− -I/R hearts, the parallel WT-I/R group showed complete recovery from the I/R injury such that no hypertrophy or fibrosis was detected in these mice. Consistently, cardiac function in WT mice was comparable with the sham group at 4 weeks post-I/R ( Figure 6A and Table) . TIMP4 −/− mice, on the other hand, exhibited suppressed systolic function and adverse remodeling, evident by increased wall thickness and LV dilation (Figure 6Ai-6Aiii) , and exacerbated LV diastolic dysfunction, evident by a marked increase in isovolumic relaxation time, deceleration time, and left atrium size and a decrease in E′-to-A′ ratio (Figure 6Aiv-6Avii) . Intriguingly, the full recovery of the WT mice at 4 weeks post-I/R was associated with an increase in TIMP4 protein to levels comparable with that in the sham group (Figure 6Bi and 6Bii ) and a concomitant normalization of MT1-MMP activity in these WT hearts ( Figure 6C ). MT1-MMP activity remained elevated in TIMP4 −/− -ischemic myocardium despite normalization of its protein levels ( Figure IIIBii in the Data Supplement) , indicating the critical importance of TIMP4 in regulating the activity of MT1-MMP. These data collectively highlight the critical role of TIMP4 in recovery from myocardial I/R injury.
Ex Vivo Ischemia-Reperfusion Resulted in Similar Postischemia Recovery in TIMP4 −/− and WT Hearts
Using the isolated heart Langendorff perfusion system, WT and TIMP4 −/− hearts were subjected to 20 minutes of global ischemia (after 15 minutes of stabilization), followed by 45 minutes of reperfusion. The perfusion buffer did not contain EDTA to avoid the complications resulting from MMP-inhibitory function of this reagent. At baseline, WT and TIMP4 −/− hearts showed comparable LV function, assessed by LV developed pressure, systolic pressure, diastolic pressures, and the rates of contraction and relaxation (±dP/dt; Figure 7A-7D) . After I/R, LV developed pressure ( Figure 7A ) and the rates of contraction and relaxation (±dP/dt, Figure 7D ) were suppressed similarly in both genotypes. This experiment was also performed with a longer ischemic period (30 minutes) and similar results were observed ( Figure IV in the Data Supplement). Heart rate was sustained and comparable in WT and TIMP4 −/− hearts throughout the protocol ( Figure 7E ). Flow rate before ischemia (2.72±0.0.27 versus 2.24 ±0.0.20 mL/min) and during reperfusion (2.38±0.28 versus 2.16±0.22 mL/min) were similar in WT and TIMP4 −/− hearts, respectively. Consistent with similar LV functions, myocyte damage post-I/R, determined by creatine kinase levels in the coronary effluent, was not different between TIMP4 −/− and WT hearts ( Figure 7F ). Therefore, TIMP4-deficient cardiomyocytes are not inherently more susceptible to ischemic injury in an ex vivo setting.
Discussion
Reperfusion of the ischemic myocardium, although an effective postischemic treatment, can trigger several adverse effects leading to myocardial dysfunction. Adverse remodeling of the myocardial ECM post-I/R can impact cardiac function. Excess degradation of the ECM by MMPs is kept under control by their inhibitors, TIMPs. In patients, MMP/TIMP balance is altered in different cardiomyopathies. 2, 4, 27 Lack of TIMPs have been shown to impair cardiac response to pressure overload 10, 28 and MI in the murine models. 10, 14, 15, 29 Among TIMPs, TIMP4 shows a tissue-specific expression pattern predominantly in the heart and brain 5 and is an effective biomarker for diastolic dysfunction in patients. 6 In this study, we report that although TIMP4 mRNA was elevated at 1 day post-I/R in WT myocardium, by 1 week post-I/R its protein and mRNA levels were reduced in the ischemic myocardium, which corresponded to diastolic dysfunction and adverse remodeling. Similarly, ischemic (noninfarct) myocardium from patients with MI showed decreased TIMP4 levels. Because lack of TIMP4 led to a far more severe diastolic dysfunction and adverse structural remodeling post-I/R, we propose that the initial increase in TIMP4 levels early post-I/R is a compensatory attempt by the myocardium to overcome the I/R-induced injury, whereas a combination of short-and long-term events lead to the subsequent decline in TIMP4 levels and structural and functional impairments by 1 week post-I/R. Intriguingly, in WT mice, TIMP4 levels recovered by 4 weeks post-I/R, which corresponded with normalization of MT1-MMP activity and amelioration of the cardiac dysfunction in these mice. Although factors such as hypoxia 30 and cytokines 31 have been reported to regulate TIMP4 expression, our findings reveal that a complex interaction between several factors could underlie this process, which will require further investigation to be unraveled.
With longer ischemic periods (30 minutes) in vivo, WT mice additionally developed systolic dysfunction although less severe than that in TIMP4 −/− mice (data not shown). However, to investigate the adverse outcomes of diastolic dysfunction in the absence of systolic dysfunction and to explore the underlying cellular and molecular mechanism of I/R injury in the absence of MI, which would ensue with longer ischemic periods, we performed the in vivo experiments with 20-minute ischemia followed by reperfusion.
Our data provide strong evidence that the inhibitory function of TIMP4 against MT1-MMP underlies the adverse myocardial remodeling and dysfunction in these mice. Consistent with our findings, reduced TIMP4 levels in the ischemic porcine myocardium correlated with elevated MT1-MMP levels and activity. 20, 32 MT1-MMP is anchored to the cell membrane, unlike other MMPs that are secreted to the extracellular space, therefore capable of coordinating the extracellular signals with cellular responses. In addition to its proteolytic functions, the cytosolic tail of MT1-MMP has been reported to induce signaling pathways such as ERK (extracellular signal-regulated kinase), 33 which can contribute to myocardial I/R injury. 34 MT1-MMP overexpression triggered myocardial fibrosis and adverse myocardial remodeling with poor outcomes post-MI, 35 whereas its enhanced activity in TIMP2 −/− mice led to nonuniform ECM remodeling and LV dilation post-MI. 16 Moreover, MT1-MMP can activate the latent TGFβ and trigger tissue fibrosis, [35] [36] [37] can activate several pro-MMPs, such as MMP2 38 and MMP13, 39 and has been associated with oxidative stress in the myocardium 40 and reactive oxygen species production. 41 In TIMP4-deficient mice, TIMP1, but not TIMP2 or TIMP3, was markedly elevated post-I/R. TIMP1 has been strongly linked to fibrosis in multiple organs, 26, 42, 43 as well as to myocardial diastolic dysfunction in different cardiomypathies. 44, 45 As such, the elevated TIMP1 in TIMP4 −/− -I/R hearts is consistent with enhanced myocardial fibrosis and the diastolic dysfunction in these mice. In addition, TIMP1 is the only TIMP that does not inhibit the MT-MMPs, as shown in this study and by others 46 and, therefore, unable to compensate for the lack of TIMP4 in inhibiting MT1-MMP post-I/R. TIMP4 deficiency did not impact the myocardial recovery after I/R ex vivo, indicating that TIMP4 deficiency does not increase the susceptibility of cardiomyocyte to I/R injury in the absence of systemic factors. Therefore, the observed dysfunction and remodeling in TIMP4 −/− -I/R mice in vivo is primarily through the cellular and molecular events, and the subsequent chronic myocardial and ECM remodeling. , and heart rate (E) in wildtype (WT) and TIMP4 −/− hearts (n=12/genotypes). F, Creatine kinase levels in the heart perfusate before ischemia (baseline) and at different times during reperfusion, n=7/genotype. *P<0.05 compared with corresponding baseline.
In summary, here we report the causal role of TIMP4 in post-I/R cardiomyopathy in the heart. The findings from our study demonstrate that TIMP4 is a critical factor in myocardial recovery from I/R injury, and variations in myocardial TIMP4 is likely a critical determinant of disease progression. We provide evidence that the post-I/R reduction in TIMP4 levels indeed mediates the subsequent diastolic dysfunction, which over time culminates to a more severe diastolic dysfunction with systolic dysfunction. Therefore, replenishment of TIMP4 in patients who exhibit reduced TIMP4 levels post-I/R could serve as an effective therapeutic approach in ischemia-reperfusion injuries. Replenishment of TIMP4 in the ischemic myocardium shortly after the onset of reperfusion could minimize reperfusion-induced injury. Because prolonged presence of TIMP4 would be required for an effective recovery from reperfusion, TIMP4 delivery to the myocardium via viral overexpression, 47 or packaging in a biodegradable material to allow its slow release, 48 could serve as effective approaches. 
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